Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03393936
Recruitment Status : Active, not recruiting
First Posted : January 9, 2018
Last Update Posted : October 21, 2021
Sponsor:
Collaborator:
Shanghai Public Health Clinical Center
Information provided by (Responsible Party):
Shanghai PerHum Therapeutics Co., Ltd.

Tracking Information
First Submitted Date  ICMJE December 25, 2017
First Posted Date  ICMJE January 9, 2018
Last Update Posted Date October 21, 2021
Actual Study Start Date  ICMJE March 26, 2018
Estimated Primary Completion Date June 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 8, 2018)
  • Phase I Safety (Incidence of adverse events defined as dose-limiting toxicities(DLT) [ Time Frame: Up to 28 days from cell infusion ]
    Incidence of adverse events defined as dose-limiting toxicities (DLT)
  • Phase II Objective Response Rate [ Time Frame: Up to 9 months from cell infusion ]
    Objective Response Rate of confirmed complete and partial remission by independent radiology review RECIST (1.1)
Original Primary Outcome Measures  ICMJE
 (submitted: January 3, 2018)
  • Phase I Safety [ Time Frame: Up to 28 days from cell infusion ]
    Incidence of adverse events defined as dose-limiting toxicities (DLT)
  • Phase II Objective Response Rate [ Time Frame: Up to 9 months from cell infusion ]
    Objective Response Rate of confirmed complete and partial remission by independent radiology review RECIST (1.1)
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Official Title  ICMJE A Dose Escalation and Dose Expansion Trial to Assess the Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) CCT 301-38 or CCT 301-59 in Patients With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Brief Summary This is a two arm, open-label, dose escalation and dose expansion clinical study to evaluate the safety and efficacy of infusion of autologous CCT301-38 or CCT 301-59 T cells in adult subjects with relapsed and refractory stage IV metastatic renal cell carcinoma.Subjects with ROR2 positive biopsy will receive CCT301-59. Subjects with AXL positive biopsy that are ROR2 negative will receive CCT301-38.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:
Subjects with ROR2 positive biopsy will receive CCT301-59. Subjects with AXL positive biopsy that are ROR2 negative will receive CCT301-38.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Renal Cell Carcinoma
Intervention  ICMJE
  • Biological: CCT301-38
    Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
  • Biological: CCT301-59
    Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
Study Arms  ICMJE
  • Experimental: CCT301-59
    The safety and efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
    Intervention: Biological: CCT301-59
  • Experimental: CCT301-38
    The safety and efficacy of CCT301-38 will be evaluated for subjects with AXL positive but ROR2 negative biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
    Intervention: Biological: CCT301-38
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: January 3, 2018)
66
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 30, 2023
Estimated Primary Completion Date June 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Men or women aged 18~70 years old.
  2. Patients are diagnosed as refractory / recurrent, Stage IV renal cell carcinoma by histological method with FDG PET signal > 3 SUV in measurable metastatic lesion.
  3. Patients with at least two metastatic lesions, including one measurable metastatic tumor lesion >10 mm measurable by CT.
  4. Tumor tissues samples confirmed CCT301 target positive IHC. Patient with histological biopsy.

    • tumor tissue with greater than or equal to 50% positive staining by IHC method for ROR2 ;
    • tumor tissue with greater than or equal to 50% positive staining by IHC method for AXL that is ROR2 negative.
  5. Expected survival ≥12 weeks.
  6. ECOG 0-1
  7. Adequate organ function as documented by:

    • ANC≥1.9X10^9/L
    • PLT≥100x10^9/L
    • Hb≥9.0g/dL
    • rCCR≥50ml/min
    • ALT and AST≤2.5ULN; for liver metastasis, ALT and AST ≤5ULN
    • Serum TBiL≤3.0mg/dL, TBiL≤2.5ULN
  8. PT: INR < 1.7 or extended PT to normal value < 4s
  9. Adequate venous access for venous blood collection, and no other contraindication of blood cell separation
  10. Patients with willingness to be in this study and able to provide informed consent
  11. Capable of receiving treatment and follow up, included patients are required to receive treatment in the enrolled centre
  12. Women of childbearing age are required to take acceptable measures to minimize the possibility of pregnancy during whole session. Women of childbearing age must have negative results of serum or urine tests within 24 hours prior to infusion. Women patients must not be in lactation;
  13. Immunological detection

    Exclusion Criteria:

  14. Pregnant women or women in lactation.
  15. Active HBV or HCV infection.
  16. HIV/AIDS infection.
  17. Active infection
  18. Previously suffered from diseases or concurrent diseases as follows:
  19. Patients confirmed as severe autoimmune diseases in long-term (over 2 months) need of systemic immune inhibitors (steroid) or as immune-mediated symptomatic diseases including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune vasculitis (for example, Wegener's granulomatosis)
  20. Patients with previous diagnosis as motor neuron disease caused by autoimmunity
  21. Patients previously suffered from toxic epidermal necrolysis (TEN)
  22. Patients with any mental diseases including dementia, mental status change that may impinge the understanding and performance of informed consent and related questionnaire
  23. Patients with severe, uncontrollable diseases judged by investigator that may hinder them receiving this treatment
  24. Patients with other previously active malignant tumors including basal or squamous skin cancer, superficial bladder cancer, and in situ breast carcinoma within 5 years who had been completely cured without the need of follow-up treatment are not excluded.
  25. Ongoing treatment using systemic steroid or steroid inhalants.
  26. Previous treatment used gene/cell therapy products.
  27. Previous experience of immunotherapies including CIK, DC, DC-CIK, LAK for the treatment of cancer.
  28. Allergic to immunotherapies or related drugs
  29. Patients in need of treatment for heart failure with ≥2 NYHA or for poor controlled hypertension.
  30. Patients with unstable or active peptic ulcer or alimentary tract hemorrhage.
  31. Patients with previous organ transplantation or ready for organ transplantation.
  32. Patients in need of anticoagulant therapy treatment (warfarin or heparin)
  33. Patients judged by investigators as not appropriate for this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03393936
Other Study ID Numbers  ICMJE CCT301-mRCC01; Phase I/II
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Shanghai PerHum Therapeutics Co., Ltd.
Study Sponsor  ICMJE Shanghai PerHum Therapeutics Co., Ltd.
Collaborators  ICMJE Shanghai Public Health Clinical Center
Investigators  ICMJE
Principal Investigator: Tongyu Zhu Shanghai Public Health Clinical Center
PRS Account Shanghai PerHum Therapeutics Co., Ltd.
Verification Date October 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP